NCT05898672View on ClinicalTrials.gov

A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 9, 2023

Primary Completion Date

August 10, 2023

Study Completion Date

August 10, 2023

Conditions
PharmacokineticsHealthy Volunteers
Interventions
DRUG

Rosuvastatin

Single oral dose of rosuvastatin tablets

DRUG

Nirmatrelvir/ritonavir

Twice daily oral doses of nirmatrelvir/ritonavir tablets

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05898672 - A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin | Biotech Hunter | Biotech Hunter